{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:49:12Z","timestamp":1793969352458,"version":"4.8.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.urolonc.2024.06.013","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T03:33:08Z","timestamp":1722396788000},"page":"374.e21-374.e29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7410-0712","authenticated-orcid":false,"given":"Takafumi","family":"Yanagisawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsushi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taizo","family":"Uchimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Tsujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhisa","family":"Nukaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Fukuokaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Yamanoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Bekku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Komura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhito","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Shiroki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoo","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.06.013_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101210","article-title":"Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the international metastatic renal cell carcinoma database consortium risk group in patients with advanced renal cell carcinoma","volume":"8","author":"Haanen","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0002","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0003","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0004","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0005","doi-asserted-by":"crossref","first-page":"LBA4501","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4501","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426","volume":"41","author":"Plimack","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0006","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European association of urology guidelines on renal cell carcinoma: the 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0007","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00262-020-02684-8","article-title":"Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis","volume":"70","author":"Mori","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0008","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.euo.2021.03.001","article-title":"First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"4","author":"Quhal","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0009","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s00345-023-04412-0","article-title":"Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis","volume":"41","author":"Yanagisawa","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0010","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00262-023-03621-1","article-title":"Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data","volume":"73","author":"Yanagisawa","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0011","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/14740338.2020.1811226","article-title":"Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis","volume":"19","author":"Massari","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0012","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.eururo.2019.07.048","article-title":"First-line immuno-oncology combination therapies in metastatic renal-cell carcinoma: results from the international metastatic renal-cell carcinoma database consortium","volume":"76","author":"Dudani","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.013_bib0013","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.euo.2023.07.003","article-title":"Real-world outcome of patients with advanced renal cell carcinoma and intermediate- or poor-risk international metastatic renal cell carcinoma database consortium criteria treated by immune-oncology combinations: differential effectiveness by risk group?","volume":"7","author":"Santoni","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0014","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.neo.2015.09.001","article-title":"Confirmatory trials in the evaluation of anticancer medicinal products in man\u2013pfs2: a measure of therapeutic action-at-a-distance","volume":"17","author":"Oronsky","year":"2015","journal-title":"Neoplasia"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0016","unstructured":"Common terminology criteria for adverse events (CTCAE) version 5.0. national cancer institute. 2017. Access January 8, 2024."},{"key":"10.1016\/j.urolonc.2024.06.013_bib0017","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0018","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jamacardio.2020.0239","article-title":"Long-term outcomes in patients with severely reduced left ventricular ejection fraction undergoing percutaneous coronary intervention vs coronary artery bypass grafting","volume":"5","author":"Sun","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0019","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/sim.5705","article-title":"The performance of different propensity score methods for estimating marginal hazard ratios","volume":"32","author":"Austin","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0020","article-title":"Dementia risk after major elective surgery based on the route of anaesthesia: a propensity score-matched population-based cohort study","volume":"55","author":"Sun","year":"2023","journal-title":"E Clin Med"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0021","doi-asserted-by":"crossref","first-page":"938.e1","DOI":"10.1016\/j.urolonc.2020.09.024","article-title":"Functional and oncological outcome of percutaneous cryoablation versus laparoscopic partial nephrectomy for clinical T1 renal tumors: a propensity score-matched analysis","volume":"38","author":"Yanagisawa","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0022","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0023","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1200\/JCO.2023.41.6_suppl.603","article-title":"Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial","volume":"41","author":"Burotto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0024","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1200\/JCO.2023.41.16_suppl.4502","article-title":"Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)","volume":"41","author":"Motzer","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0025","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s11523-023-00978-2","article-title":"Global real-world outcomes of patients receiving immuno-oncology combinations for advanced renal cell carcinoma: the ARON-1 study","volume":"18","author":"Santoni","year":"2023","journal-title":"Target Oncol"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"385","key":"10.1016\/j.urolonc.2024.06.013_bib0027","doi-asserted-by":"crossref","first-page":"eaak9679","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation","volume":"9","author":"Allen","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0028","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1158\/2326-6066.CIR-14-0244","article-title":"Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma","volume":"3","author":"Liu","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0029","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0030","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0031","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0032","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2217\/imt-2021-0207","article-title":"Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis","volume":"14","author":"Yanagisawa","year":"2022","journal-title":"Immunotherapy"},{"issue":"22","key":"10.1016\/j.urolonc.2024.06.013_bib0033","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.3390\/cancers14225659","article-title":"Serum C-reactive protein level predicts overall survival for clear cell and non-clear cell renal cell carcinoma treated with ipilimumab plus nivolumab","volume":"14","author":"Yano","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0034","doi-asserted-by":"crossref","first-page":"e1151","DOI":"10.1016\/j.clgc.2018.07.027","article-title":"Higher serum c-reactive protein level represents the immunosuppressive tumor microenvironment in patients with clear cell renal cell carcinoma","volume":"16","author":"Nakayama","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"13","key":"10.1016\/j.urolonc.2024.06.013_bib0035","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.3390\/cancers14133127","article-title":"RCC real-world data: prognostic factors and risk stratification in the immunotherapy era","volume":"14","author":"Sagie","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0036","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.06.013_bib0037","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41585-022-00676-0","article-title":"Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma","volume":"20","author":"Rosellini","year":"2023","journal-title":"Nat Rev Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924005283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924005283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T10:49:32Z","timestamp":1725360572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924005283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1078143924005283"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.06.013","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}